相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results
Geert R. D'Haens et al.
GASTROENTEROLOGY (2022)
Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives
Konstantinos Papamichael et al.
Lancet Gastroenterology & Hepatology (2022)
Comparison of a new rapid method for the determination of adalimumab serum levels with two established ELISA kits
Emilio J. Laserna-Mendieta et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2019)
Accuracy of the new rapid test for monitoring adalimumab levels
Catia Rocha et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2019)
Therapeutic drug monitoring of anti-TNF therapy in children with inflammatory bowel disease
Karen van Hoeve et al.
EXPERT OPINION ON DRUG SAFETY (2018)
Adalimumab trough levels predict Crohn's disease clinical course
Davide Giuseppe Ribaldone et al.
DIGESTIVE AND LIVER DISEASE (2018)
Population-based cohort study on comparative effectiveness and safety of biologics in inflammatory bowel disease
Riccardo Di Domenicantonio et al.
CLINICAL EPIDEMIOLOGY (2018)
Development and validation of an optical biosensor for rapid monitoring of adalimumab in serum of patients with Crohn's disease
Sumin Bian et al.
DRUG TESTING AND ANALYSIS (2018)
American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease
Joseph D. Feuerstein et al.
GASTROENTEROLOGY (2017)
Tissue Drug Concentrations of Anti-tumor Necrosis Factor Agents Are Associated with the Long-term Outcome of Patients with Crohn's Disease
Takeo Yoshihara et al.
INFLAMMATORY BOWEL DISEASES (2017)
Serum Adalimumab Levels Predict Successful Remission and Safe Deintensification in Inflammatory Bowel Disease Patients in Clinical Practice
Mariam Aguas Peris et al.
INFLAMMATORY BOWEL DISEASES (2017)
Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases
N. Mitrev et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases
Bella Ungar et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
Higher Adalimumab Levels Are Associated with Histologic and Endoscopic Remission in Patients with Crohn's Disease and Ulcerative Colitis
Andres J. Yarur et al.
INFLAMMATORY BOWEL DISEASES (2016)
Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn's disease
Giorgia Bodini et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2016)
Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease
Y. Mazor et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
Association Between Pharmacokinetics of Adalimumab and Mucosal Healing in Patients With Inflammatory Bowel Diseases
Xavier Roblin et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2014)
Pharmacokinetics of Adalimumab in Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis
Stephane Paul et al.
INFLAMMATORY BOWEL DISEASES (2014)
Serum Adalimumab Concentration and Clinical Remission in Patients with Crohn's Disease
Yi-Lin Chiu et al.
INFLAMMATORY BOWEL DISEASES (2013)
Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease
R. Panaccione et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2010)
Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease
Konstantinos Karmiris et al.
GASTROENTEROLOGY (2009)
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial
W. J. Sandborn et al.
GUT (2007)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
Jean-Frederic Colombel et al.
GASTROENTEROLOGY (2007)
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial
SB Hanauer et al.
GASTROENTEROLOGY (2006)
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology
Mark S. Silverberg et al.
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2005)
Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD
M Daperno et al.
GASTROINTESTINAL ENDOSCOPY (2004)
分享论文
